Citius Pharmaceuticals shares surge 20.19% after-hours after launching LYMPHIR and securing $61 million in funding.

Citius Pharmaceuticals (CTXR) surged 20.19% in after-hours trading following the launch of its FDA-approved cancer immunotherapy LYMPHIR by subsidiary Citius Oncology in December 2025. The drug, the first new systemic therapy for CTCL patients since 2018, marked a pivotal shift to revenue generation for the company. Strategic financings raised $61 million, with $25 million from Citius Pharma and $36 million from Citius Oncology, bolstering commercialization efforts. LYMPHIR’s inclusion in NCCN guidelines and distribution agreements with U.S. wholesalers, alongside international access via 19 markets through named patient programs, highlighted its commercial potential. Despite reporting a $39.7 million net loss for fiscal 2025, the launch and capital raises signaled progress toward addressing a $400 million U.S. market gap, driving investor optimism.